Lurbinectedin, a potential antitumor agent shows promise in Ewing’s sarcoma patients, who generally have poor outcomes. Recently, results of a phase II clinical trial demonstrated that Lurbinectedin has clear antitumor activity along with favourable safety and tolerability as a single agent in patients with advanced or relapsed Ewing sarcoma. Among the all available treatment options, what is your opinion regarding clinical utility of Lurbinectedin In Ewing Sarcoma?
Reference Lurbinectedin Effective in Early Trial of Advanced Ewing Sarcoma. 2017 Connective Tissue Oncology Society Annual Meeting
